Virtuix Q1FY27 sales beat estimates, gross margin expands to 30%
Virtuix Holdings reported Q1FY27 sales of $767.300K, beating estimates. Gross margin expanded to 30% from 17% due to higher pricing. New orders rose 72% YoY. The company faces a widened net loss due to public company costs and non-cash charges, with a cash burn of ~$1M/month.

*this image is generated using AI for illustrative purposes only.
Virtuix Holdings Inc. (NASDAQ: VTIX) reported first quarter fiscal year 2027 results that exceeded analyst expectations, with net sales reaching $767.300K against an estimate of $535.667K. The company also posted a net loss per share of ($0.22), beating the consensus estimate of a ($0.24) loss. The improved top-line performance reflects a strategic shift from backlog clearance to new customer acquisition, despite the completion of the final batch of legacy Omni One orders accumulated since August 2023.
Despite the lower top line compared to the prior year, unit economics improved significantly. Gross profit rose 29% to $227,158 from $176,077 in the prior-year period, driving gross margin expansion to 30% from 17%. This improvement was primarily attributed to higher selling prices for the complete Omni One system compared to units delivered in the previous year. Management noted that pricing for the complete system increased from $2,595 to $3,495 in November of the prior year, while new products like Omni One for Quest are priced at $2,595.
Operational Highlights
New order momentum accelerated during the quarter:
- New orders for Omni One systems increased 72% year-over-year.
- Orders have risen approximately 150% since the launch of Omni One for Quest, a trend continuing into the current quarter.
- The company secured its first Omni One Enterprise sale to Tesla Inc. for humanoid robot teleoperation.
- Defense sector advancements include the U.S. Marine Corps Infantry Fireteam Trainer pilot delivery expected in Q4 2026 and an SBIR Phase I award from the U.S. Air Force.
Financial Performance
The bottom line was pressured by increased operating costs and non-cash charges. Total operating expenses rose 86% to $4.1 million from $2.2 million, driven by a $0.7 million increase in stock-based compensation and $1.2 million in professional services fees related to public company operations. Other expenses surged to $3.2 million from $0.2 million, largely due to $2.5 million in interest expense and amortization of debt discount on convertible notes. Approximately $4 million of the net loss consisted of non-cash charges.
| Metric: | Q1FY27 | Q1FY26 | Change |
|---|---|---|---|
| Net Sales: | $0.8 million | $1.0 million | -26% |
| Gross Profit: | $227,158 | $176,077 | +29% |
| Gross Margin: | 30% | 17% | +13 pts |
| Operating Expenses: | $4.1 million | $2.2 million | +86% |
| Net Loss: | ($7.2) million | ($2.3) million | Widened |
| Adjusted EBITDA Loss: | ($3.1) million | ($1.9) million | Widened |
Net loss per share narrowed to ($0.22) from ($0.28). Cash and cash equivalents stood at $7.4 million as of June 30, 2026, down from $9.5 million at March 31, 2026. Management indicated a cash burn run rate of approximately $1 million per month, elevated due to public company costs. Inventory increased to $1.4 million as the company builds for order growth. Total liabilities were $15.7 million, including $10.7 million of notes payable, net of discount.
Strategic Outlook
Management outlined six priorities for the coming periods:
- Accelerate consumer revenue growth through the Meta collaboration.
- Advance defense programs towards larger awards, including moving Air Force SBIR Phase I to Phase II.
- Pursue M&A in defense, targeting acquisitions with $10 million to $50 million in annual revenue.
- Expand enterprise sales, building on traction with Tesla and NASA.
- Build out healthcare and therapeutics verticals via partnerships with Sirica Therapeutics.
- Drive toward profitability, leveraging the improved 30% gross margin.
Production capacity is established at up to 3,000 units per month, translating to approximately $100 million in annual revenues. The company aims to bundle Omni One for Quest with Meta headsets for the holiday season.
What the Numbers Show
The divergence between revenue decline and gross profit growth highlights a pricing-driven margin expansion rather than volume-led growth. With gross profit rising 29% despite a 26% revenue drop, the company is realizing significantly higher value per unit sold. However, this operational improvement was insufficient to offset the 86% surge in operating expenses and substantial non-cash interest charges, resulting in a widened net loss. The cash burn of approximately $2 million in the quarter underscores the need for continued capital efficiency or financing as the company transitions from backlog fulfillment to new customer acquisition.
Given the current cash burn rate of $1 million per month and $7.4 million in cash reserves, what is Virtuix's timeline for reaching cash-flow positivity or requiring additional capital raising?
How might the strategic M&A focus on defense companies with $10M-$50M in revenue impact Virtuix's debt load and integration costs in the near term?
Will the bundling of Omni One for Quest with Meta headsets during the holiday season significantly alter the company's gross margin profile compared to standalone sales?

































